Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 3, 2014, Pages 241-256

  Zhang, Yifei ^a,b   Hong, Jie ^a,b   Chi, Jie ^a,b   Gu, Weiqiong ^a,b   Ning, Guang ^a,b   Wang, Weiqing ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Body weight; Dipeptidyl peptidase IV; Efficacy; Hypoglycaemia; Safety; Sulfonylureas; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; DATA ANALYSIS; DRUG COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INFORMATION RETRIEVAL; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

BODY WEIGHT; DIPEPTIDYL PEPTIDASE-IV; EFFICACY; HYPOGLYCAEMIA; SAFETY; SULFONYLUREAS; TYPE 2 DIABETES;

CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84895467669     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2482     Document Type: Article

References (46)

1. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531-537.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
3. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
4. Nathan DM, Buse J, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes a consensus algorithm for the initiation and adjustment of therapy a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2009; 32: 193-203.
5. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
7. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008; 168: 2088-2094.
8. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68: 2131-2162.
9. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339-1358.
10. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
11. Ahrén B. Are sulphonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? Curr Diab Rep 2011; 11: 83-90.
12. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-IV inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594-603.
13. Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010; 375: 1410-1412.
14. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes a critical review of head-to-head trials. Diabetes Metab 2012; 38: 89-101.
15. Scheen AJ, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet 2012; 380: 450-452.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
18. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.
19. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13: 160-168.
20. Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Physicians India 2012; 60: 27-30.
21. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronicrenal insufficiency. Diabetes Care 2013; 36: 1067-1073.
22. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis a 54-week randomized trial. Am J Kidney Disss 2013; 61: 579-587.
23. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulphonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009; 41: 905-909.
24. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-789.
25. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone a 52-week, randomized study. Diabet Med 2010; 27: 318-326.
26. Jeon HJ, Oh TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 2011; 35: 529-535.
27. Göke B, Gallwitz B, Eriksson JG, Hellqvist Å, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013; 67: 307-316.
28. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin a randomised, double-blind, non-inferiority trial. Lancet 2012; 380: 475-483.
29. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013; 15: 906-914.
30. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
31. Gribble FM, Reimann F. Sulphonylurea action revisited: the postcloning area. Diabetologia 2003; 46: 875-891.
32. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994; 8: 201-203.
33. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245-254.
34. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012; 34: 1247-1258.e22
35. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP1 analogues and DPP-4 inhibitors. Exp Opin Investig Drug 2009; 18: 1495-1503.
36. Dhillon S. Sitagliptin a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 489-512.
37. Deacon CF, Holst JJ. Saxagliptin a new dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26: 488-499.
38. Deacon CF, Holst JJ. Linagliptin a xanthine-based dipeptidyl peptidase-IV inhibitor with an unusual profile for the treatment of type 2 diabetes. Exp Opin Invest Drugs 2010; 19: 133-140.
39. Pratley RE. Alogliptin a new, highly selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Exp Opin Pharmacother 2009; 20: 503-512.
40. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.
41. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004; 58: 833-837.
42. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
43. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012; 46: 1453-1469.
44. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metforminon glycaemic control, hypoglycaemia and weight change inpatients with type 2 diabetes a network meta-analysis. Diabetes Obes Metab 2012; 14: 810-820.
45. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.
46. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20: 224-235.